**Company Profile**

**Industry Sector:** Tools for biomedical research & human wellness assessment  

**Company Overview:** Oxford Biomedical Research (OBR) develops, manufactures, and markets products for research on biomarkers for oxidative stress and chronic inflammation, two major factors known to be involved in the development of many diseases. OBR is launching a new company to manufacture and market metabolic and oxidative stress biomarker assays in formats suitable for routine assessment of human wellness.

**Target Market(s):** Oxidative stress and inflammation research market; point-of care testing of human wellness and disease risk.

---

**Management**

**Leadership:**  
Denis M. Callewaert, Ph.D. President & CEO  
Richard McGowen, M.S. Director of Marketing  
Matthew Hymes, M.S., MBA, Director of Product Development  
Thomas Brown, Ph.D. Senior Scientist  
Enrique Martinez, Ph.D. Senior Scientist

**Scientific Advisory Board:**  
Fazlul H. Sarkar, Ph.D., Department of Pathology, Wayne State University, Expertise: Nutraceuticals and the risk & progression of cancer  
Samar Basu, Ph.D. Department of Nutrition, Uppsula University, Expertise: Biomarkers for oxidative stress and Inflammation  
Jean-Marie Dimandja, Ph.D., Department of Chemistry, Spelman College, Expertise: Comprehensive GC/MS separation technology

---

**Key Value Drivers**

**Technology:** OBR has numerous assays for oxidative damage, total antioxidant capacity and inflammation. The new firm will develop specific tests for protein and metabolic biomarkers associated with risk for Alzheimer’s disease and cancer, including a novel multi-dimensional separation technology that will generate disease-specific "metabolic fingerprints" from routine urine samples.

**Competitive Advantage:** We will leverage OBR’s 24-year track record and recognized leadership in oxidative stress and inflammation testing to meet the needs of a new market. This expertise, along with our proprietary and patented technologies, will differentiate us from companies with less experience and scientific validity.

**Plan & Strategy:** Although over 70% of Americans take dietary supplements, there are presently no available tests to determine if they are necessary or effective. Many supplements tout antioxidant action, and our initial product line will assess an individual’s oxidative status and antioxidant capacity. Point-of-care tests for antioxidant capacity, oxidative stress and inflammation will be marketed via the internet, and through partnerships with health care providers promoting wellness.

---

**Product Pipeline**

**Phase 1:** Simple tests to quantify (a) antioxidant capacity, (b) lipid oxidation, and (c) creatinine (to adjust for urine concentration) – providing a heretofore unavailable means to assess an individual’s oxidative status, a risk factor for many diseases.

**Phase 2:** Tests for specific oxidized proteins that correlate with the risk of specific diseases, and a cancer resistance biomarker.

**Phase 3:** A novel instrument and software for the rapid and inexpensive identification of "metabolic fingerprints" for early diagnosis of chronic and acute diseases.

---

**Opportunities**

We are looking for investors, organizations, or individuals interested in collaborating with us to explore nutraceutical efficacy testing and/or early diagnosis of human diseases.